Abstract: ObjectiveThis study evaluated the prognostic power of serum uric acid (UA) in predicting adverse events in elderly acute coronary syndrome (ACS) patients with diabetes mellitus (DM).
MethodsThe analysis involved 718 ACS patients‍>80 years old whose general clinical data and baseline blood biochemical indicators were collected prospectively from January 2006 to December 2012. These patients were classified into two groups based on DM status, and then followed up after discharge. The Kaplan-Meier method was used for major adverse cardiac event (MACE) rates and all-cause mortality. Multivariate Cox regression was performed to analyze the relationship between UA level and long-term clinical prognosis. Receiver operating characteristic (ROC) curves were analyzed to predict the cutoff value of UA in elderly ACS patients with DM. There were 242 and 476 patients in the DM and non-DM (NDM) groups, respectively, and the follow-up time after discharge was 40‒120 months (median, 63 months; interquartile range, 51‒74 months).
ResultsThe all-cause mortality, cardiac mortality, and MACE rates in both DM and NDM patients were higher than those in the control group (P=0.001). All-cause mortalities, cardiac mortalities, and MACE rates in DM patients with moderate and high UA levels were significantly higher than those in the NDM group (P=0.001). Long-term survival rates decreased significantly with increased UA levels in the ACS groups (P=0.001). UA (odds ratio (OR)=2.106, 95% confidence interval (CI)=1.244‒3.568, P=0.006) was found to be an independent risk factor for all-cause mortality and MACE in elderly ACS patients with DM. The cutoff value of UA was 353.6 μmol/L (sensitivity, 67.4%; specificity, 65.7%).
ConclusionsSerum UA level is a strong independent predictor of long-term all-cause death and MACE in elderly ACS patients with DM.

血清尿酸对合并糖尿病的高龄急性冠状动脉综合征患者预后能力的评价:一项前瞻性队列研究

[1]BaileyCJ, 2019. Uric acid and the cardio-renal effects of SGLT2 inhibitors. Diabetes Obes Metab, 21(6):1291-1298.

[2]BonacaMP, GutierrezJA, CannonC, et al., 2018. Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT TRIAL. Lancet Diabetes Endocrinol, 6(12):934-943.

[3]CiceroAFG, FogacciF, GiovanniniM, et al., 2018. Serum uric acid predicts incident metabolic syndrome in the elderly in an analysis of the Brisighella Heart Study. Sci Rep, 8:11529.

[4]Contreras-ZentellaML, Sánchez-SevillaL, Suárez-CuencaJA, et al., 2019. The role of oxidant stress and gender in the erythrocyte arginine metabolism and ammonia management in patients with type 2 diabetes. PLoS ONE, 14(7):e0219481.

[5]FiorentinoTV, SestiF, SuccurroE, et al., 2018. Higher serum levels of uric acid are associated with a reduced insulin clearance in non-diabetic individuals. Acta Diabetol, 55(8):835-842.

[6]FuZH, XueH, GuoJ, et al., 2013. Long-term prognostic impact of cystatin C on acute coronary syndrome octogenarians with diabetes mellitus. Cardiovasc Diabetol, 12:157.

[7]GertlerMM, GarnSM, LevineSA, 1951. Serum uric acid in relation to age and physique in health and in coronary heart disease. Ann Intern Med, 34(6):1421-1431.

[8]GrossmanC, GrossmanE, GoldbourtU, 2019. Uric acid variability at midlife as an independent predictor of coronary heart disease and all-cause mortality. PLoS ONE, 14(8):e0220532.

[9]GuoXX, WangY, WangK, et al., 2018. Stability of a type 2 diabetes rat model induced by high-fat diet feeding with low-dose streptozotocin injection. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 19(7):559-569.

[10]GuoXZ, QinY, ZhengK, et al., 2014. Improved glomerular filtration rate estimation using new equations combined with standardized cystatin C and creatinine in Chinese adult chronic kidney disease patients. Clin Biochem, 47(13-14):1220-1226.

[11]JinDY, LiuCL, TangJN, et al., 2017. Interleukin-18, matrix metalloproteinase-22 and -29 are independent risk factors of human coronary heart disease. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 18(8):685-695.

[12]KeermanM, YangF, HuH, et al., 2020. Mendelian randomization study of serum uric acid levels and diabetes risk: evidence from the Dongfeng-Tongji cohort. BMJ Open Diabetes Res Care, 8:e000834.

[13]KimuraY, YanagidaT, OndaA, et al., 2020. Soluble uric acid promotes atherosclerosis via AMPK (AMP-activated protein kinase)-mediated inflammation. Arterioscler Thromb Vasc Biol, 40(3):570-582.

[14]KomaruY, TakeuchiT, SuzukiL, et al., 2019. Recurrent cardiovascular events in patients with newly diagnosed acute coronary syndrome: influence of diabetes and its management with medication. J Diabetes Complications, 34(3):107511.

[15]KramerCK, von MühlenD, JassalSK, et al., 2010. A prospective study of uric acid by glucose tolerance status and survival: the Rancho Bernardo Study. J Intern Med, 267(6):561-566.

[16]LazzeroniD, BiniM, CamaioraU, et al., 2018. Serum uric acid level predicts adverse outcomes after myocardial revascularization or cardiac valve surgery. Eur J Prev Cardiol, 25(2):119-126.

[17]LevantesiG, MarfisiRM, FranzosiMG, et al., 2013. Uric acid: a cardiovascular risk factor in patients with recent myocardial infarction. Int J Cardiol, 167(1):262-269.

[18]LuTY, ForgettaV, YuOHY, et al., 2020. Polygenic risk for coronary heart disease acts through atherosclerosis in type 2 diabetes. Cardiovasc Diabetol, 19:12.

[19]MaYC, ZuoL, ChenJH, et al., 2006. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol, 17(10):2937-2944.

[20]ManiP, PuriR, SchwartzGG, et al., 2019. Association of initial and serial C-reactive protein levels with adverse cardiovascular events and death after acute coronary syndrome: a secondary analysis of the VISTA-16 trial. JAMA Cardiol, 4(4):314-320.

[21]National Center for Cardiovascular Diseases, 2021. Annual report on cardiovascular health and diseases in China (2020). J Cardiovasc Med (Hagerstown), 3:276 (in Chinese).

[22]NdrepepaG, 2018. Uric acid and cardiovascular disease. Clinica Chimica Acta, 484:150-163.https://doi: 10.1016/j.cca.2018.05.046

[23]NishidaY, TakahashiY, SusaN, et al., 2013. Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study. Cardiovasc Diabetol, 12:159.

[24]PerticoneF, SciacquaA, PerticoneM, et al., 2012. Serum uric acid and 1-h postload glucose in essential hypertension. Diabetes Care, 35(1):153-157.

[25]PullingerCR, O'ConnorPM, Naya-VigneJM, et al., 2021. Levels of prebeta-1 high-density lipoprotein are a strong independent positive risk factor for coronary heart disease and myocardial infarction: a meta-analysis. J Am Heart Assoc, 10(7):e018381.

[26]PurnimaS, El-AalBGA, 2016. Serum uric acid as prognostic marker of coronary heart disease (CHD). Clin Investig Arterioscler, 28(5):216-224.

[27]Ruszkowska-CiastekB, SokupA, WernikT, et al., 2015. Effect of uncontrolled hyperglycemia on levels of adhesion molecules in patients with diabetes mellitus type 2. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 16(5):355-361.

[28]SaitoY, KitaharaH, NakayamaT, et al., 2019. Relation of elevated serum uric acid level to endothelial dysfunction in patients with acute coronary syndrome. J Atheroscler Thromb, 26(4):362-367.

[29]SethiSS, AklEG, FarkouhME, 2012. Diabetes mellitus and acute coronary syndrome: lessons from randomized clinical trials. Curr Diab Rep, 12(3):294-304.

[30]SpigaR, MariniMA, MancusoE, et al., 2017. Uric acid is associated with inflammatory biomarkers and induces inflammation via activating the NF-κB signaling pathway in HepG2 cells. Arterioscler Thromb Vasc Biol, 37(6):1241-1249.

[31]TassoneEJ, CimellaroA, PerticoneM, et al., 2018. Uric acid impairs insulin signaling by promoting ENPP1 binding to insulin receptor in human umbilical vein endothelial cells. Front Endocrinol (Lausanne), 9:98.

[32]TimóteoAT, LousinhaA, LabandeiroJ, et al., 2013. Serum uric acid: a forgotten prognostic marker in acute coronary syndromes? Eur Heart J Acute Cardiovasc Care, 2(1):44-52.

[33]TscharreM, HermanR, RohlaM, et al., 2018. Uric acid is associated with long-term adverse cardiovascular outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Atherosclerosis, 270:173-179.

[34]TsujitaK, YamanagaK, KomuraN, et al., 2016. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: subanalysis of PRECISE-IVUS trial. Atherosclerosis, 251:367-372.

[35]VermaS, JiQH, BhattDL, et al., 2020. Association between uric acid levels and cardio-renal outcomes and death in patients with type 2 diabetes: a subanalysis of EMPA-REG OUTCOME. Diabetes Obes Metab, 22(7):1207-1214.

[36]WangCW, YanWL, WangH, et al., 2019. APOE polymorphism is associated with blood lipid and serum uric acid metabolism in hypertension or coronary heart disease in a Chinese population. Pharmacogenomics, 20(14):1021-1031.

[37]WangRJ, SongYX, YanYQ, et al., 2016. Elevated serum uric acid and risk of cardiovascular or all-cause mortality in people with suspected or definite coronary artery disease: a meta-analysis. Atherosclerosis, 254:193-199.

[38]WannametheeSG, PapacostaO, LennonL, et al., 2018. Serum uric acid as a potential marker for heart failure risk in men on antihypertensive treatment: the British Regional Heart Study. Int J Cardiol, 252:187-192.

[39]WeiXB, JiangL, LiuYH, et al., 2017. Serum uric acid as a simple risk factor in patients with rheumatic heart disease undergoing valve replacement surgery. Clin Chim Acta, 472:69-74.

[40]XuRJ, KongWM, AnXF, et al., 2020. Physiologically-based pharmacokinetic-pharmacodynamics model characterizing CYP2C19 polymorphisms to predict clopidogrel pharmacokinetics and its anti-platelet aggregation effect following oral administration to coronary artery disease patients with or without diabetes. Front Pharmacol, 11:593982.

[41]YuW, ChengJD, 2020. Uric acid and cardiovascular disease: an update from molecular mechanism to clinical perspective. Front Pharmacol, 11:582680.

[42]ZhaoZL, ZhaoYS, ZhangYQ, et al., 2021. Gout-induced endothelial impairment: the role of SREBP2 transactivation of YAP. FASEB J, 35(6):e21613.

[43]ZhouX, LiJQ, WeiLJ, et al., 2020. Silencing of DsbA-L gene impairs the PPARγ agonist function of improving insulin resistance in a high-glucose cell model. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 21(12):990-998.